Last reviewed · How we verify
methylphenidate HCl ERCT
Methylphenidate HCl ERCT is an extended-release formulation that inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.
Methylphenidate HCl ERCT is an extended-release formulation that inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Narcolepsy.
At a glance
| Generic name | methylphenidate HCl ERCT |
|---|---|
| Sponsor | Pfizer |
| Drug class | Sympathomimetic amine; central nervous system stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing the reuptake of these neurotransmitters from the synaptic cleft back into presynaptic neurons. The extended-release controlled-release technology (ERCT) formulation provides sustained drug delivery over an extended period, maintaining therapeutic levels throughout the day. This mechanism enhances attention, focus, and impulse control in patients with attention deficit hyperactivity disorder.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness/anxiety
- Tachycardia
- Abdominal pain
- Weight loss
Key clinical trials
- Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. (PHASE4)
- A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD (PHASE4)
- A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methylphenidate HCl ERCT CI brief — competitive landscape report
- methylphenidate HCl ERCT updates RSS · CI watch RSS
- Pfizer portfolio CI